141 related articles for article (PubMed ID: 9408807)
1. Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men.
Martin DE; Zussman BD; Everitt DE; Benincosa LJ; Etheredge RC; Jorkasky DK
J Clin Psychopharmacol; 1997 Dec; 17(6):451-9. PubMed ID: 9408807
[TBL] [Abstract][Full Text] [Related]
2. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
Abernethy DR; Barbey JT; Franc J; Brown KS; Feirrera I; Ford N; Salazar DE
Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Bergstrom RF; Goldberg MJ; Cerimele BJ; Hatcher BL
Clin Pharmacol Ther; 1997 Dec; 62(6):643-51. PubMed ID: 9433393
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
Awni WM; Cavanaugh JH; Leese P; Kasier J; Cao G; Locke CS; Dube LM
Eur J Clin Pharmacol; 1997; 52(1):49-54. PubMed ID: 9143867
[TBL] [Abstract][Full Text] [Related]
5. Azithromycin and terfenadine: lack of drug interaction.
Harris S; Hilligoss DM; Colangelo PM; Eller M; Okerholm R
Clin Pharmacol Ther; 1995 Sep; 58(3):310-5. PubMed ID: 7554704
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Wright CE; Shader RI
J Clin Psychopharmacol; 1996 Apr; 16(2):104-12. PubMed ID: 8690825
[TBL] [Abstract][Full Text] [Related]
7. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers.
Robbins B; Chang CT; Cramer JA; Garreffa S; Hafkin B; Hunt TL; Meligeni J
Clin Pharmacol Ther; 1996 Mar; 59(3):275-83. PubMed ID: 8653990
[TBL] [Abstract][Full Text] [Related]
8. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers.
Wong SL; Cao G; Mack R; Granneman GR
Int J Clin Pharmacol Ther; 1998 Mar; 36(3):146-51. PubMed ID: 9562230
[TBL] [Abstract][Full Text] [Related]
9. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.
Clifford CP; Adams DA; Murray S; Taylor GW; Wilkins MR; Boobis AR; Davies DS
Eur J Clin Pharmacol; 1997; 52(4):311-5. PubMed ID: 9248771
[TBL] [Abstract][Full Text] [Related]
10. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
[TBL] [Abstract][Full Text] [Related]
11. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers.
Saruwatari J; Yasui-Furukori N; Niioka T; Akamine Y; Takashima A; Kaneko S; Uno T
J Clin Psychopharmacol; 2012 Apr; 32(2):195-9. PubMed ID: 22367658
[TBL] [Abstract][Full Text] [Related]
12. The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.
Kadokura T; den Adel M; Krauwinkel WJ; Takeshige T; Nishida A
Eur J Clin Pharmacol; 2008 Jun; 64(6):605-9. PubMed ID: 18401578
[TBL] [Abstract][Full Text] [Related]
13. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.
Honig PK; Wortham DC; Zamani K; Conner DP; Mullin JC; Cantilena LR
JAMA; 1993 Mar 24-31; 269(12):1513-8. PubMed ID: 8445813
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine.
Stern RH; Smithers JA; Olson SC
J Clin Pharmacol; 1998 Aug; 38(8):753-7. PubMed ID: 9725552
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.
Gupta S; Banfield C; Kantesaria B; Marino M; Clement R; Affrime M; Batra V
Clin Ther; 2001 Mar; 23(3):451-66. PubMed ID: 11318079
[TBL] [Abstract][Full Text] [Related]
16. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram.
Benton RE; Honig PK; Zamani K; Cantilena LR; Woosley RL
Clin Pharmacol Ther; 1996 Apr; 59(4):383-8. PubMed ID: 8612381
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers.
Briciu C; Neag M; Muntean D; Vlase L; Bocsan C; Buzoianu A; Gheldiu AM; Achim M; Popa A
J Clin Pharm Ther; 2014 Oct; 39(5):535-40. PubMed ID: 24845234
[TBL] [Abstract][Full Text] [Related]
18. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole.
Banfield C; Herron J; Keung A; Padhi D; Affrime M
Clin Pharmacokinet; 2002; 41 Suppl 1():37-44. PubMed ID: 12169045
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine.
Pesco-Koplowitz L; Hassell A; Lee P; Zhou H; Hall N; Wiesinger B; Mechlinski W; Grover M; Hunt T; Smith R; Travers S
J Clin Pharmacol; 1999 Jan; 39(1):76-85. PubMed ID: 9987703
[TBL] [Abstract][Full Text] [Related]
20. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.
Stout SM; Nielsen J; Bleske BE; Shea M; Brook R; Kerber K; Welage LS
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):373-9. PubMed ID: 20705902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
